FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552783193> ?p ?o ?g. }

• W2552783193 abstract "Abstract Purpose and design The effect of HLA-identical sibling donor (ISDs) haematopoietic stem cell transplantation (HSCT) on adults with high-risk acute lymphoblastic leukaemia (ALL) in the first complete remission (CR1) has been established. Our recent single-institute, retrospective study showed that haploidentical HSCT was superior to chemotherapy alone for patients with high-risk ALL in CR1. To test the hypothesis that haploidentical HSCT would be a valid option as post-remission therapy for ALL patients in CR1 lacking a matched donor, we designed a disease-specific, prospective, multi-centre study. Patients Between July 2010 and Dec 2013, 186 patients with Philadelphia-negative high-risk ALL were biologically randomized to undergo un-manipulated HIDs (103 patients) or ISDs HSCT (83 patients) according to donor availability. Results Among HIDs and ISDs recipients, the 3-year disease free survival (DFS) rate was 68% and 64% (P =.56), respectively; overall survival (OS) rate was 75% and 69% (P = .51, respectively; cumulative incidences of relapse were 18% and 24% (P = .30), and those of the non-relapse-mortality (NRM) were 13% and 11% (P = .84), respectively. The 28-d myeloid recovery rates were both 99% in each group; the incidences of severe acute graft-versus-host-disease (GVHD) and chronic GVHD were also comparable between the two groups. Among recipients of transplantations from HIDs, no significant differences in DFS, OS, or NRM were observed between 3/6 and 4-5/6 matched grafts; in contrast, maternal donor was related with lower OS compared with other donor sources (P = .04); limited chronic GVHD was associated with better DFS (P = .01). The stem cell source had no effect on DFS. Conclusion Un-manipulated haploidentical-HSCT achieves outcomes similar to those of ISD-HSCT for Philadelphia-negative high-risk ALL patients in CR1. Such transplantation was proved to be a valid alternative as post-remission treatment for high-risk ALL patients in CR1 lacking an identical donor. (Chictr.org.cn number ChiCTR-OCH-10000940) Table. Results of multivariate analysis of outcomes Outcome Hazard ratio (95%Confidence interval) p value Disease free survival Haploidentical vs Identical sibling 0.88 (0.50-1.53) .65 Patient age <30 vs >30 years 0.74 (0.42-1.28) .28 Patient sex male vs female 1.13 (0.55-2.30) .74 Time to transplant <6 vs >6 months 1.48 (0.86-2.56) .16 Female-to-male vs other sex pair 0.95(0.52-1.75) .86 Limited chronic GVHD vs no or extended 0.59 (0.29-1.17) .13 Overall survival Haploidentical vs Identical sibling 0.91 (0.50-1.70) .77 Patient age <30 vs >30 years 0.60 (0.33-1.11) .11 Patient sex male vs female 1.13 (0.55-2.30) .74 Time to transplant <6 vs >6 months 1.64 (0.89-3.01) .11 Female-to-male vs other sex pair 1.22 (0.64-2.31) .54 Limited chronic GVHD vs no or extended 0.59 (0.27-1.28) .18 Relapse Haploidentical vs Identical sibling 0.67(0.33-1.36) .27 Patient age <30 vs >30 years 1.06 (0.50-2.28) .87 Patient sex male vs female 1.52 (0.64-3.62) .35 Time to transplant <6 vs >6 months 1.42 (0.69-2.90) .33 Female-to-male vs other sex pair 0.61(0.26-1.45) .27 Limited chronic GVHD vs no or extended 0.65 (0.26-1.62) .36 Non-Relapse-Mortality Haploidentical vs Identical sibling 1.38(0.58-3.35) .46 Patient age <30 vs >30 years 0.47 (0.19-1.17) .11 Patient sex male vs female 0.66 (0.19-2.33) .52 Time to transplant <6 vs >6 months 1.66 (0.70-3.92) .25 Female-to-male vs other sex pair 1.53(0.64-3.69) .34 Limited chronic GVHD vs no or extended 0.63 (0.21-1.86) .40 Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W2552783193 created "2016-11-30" @default.
• W2552783193 creator A5006739024 @default.
• W2552783193 creator A5032457247 @default.
• W2552783193 creator A5037029781 @default.
• W2552783193 creator A5061407928 @default.
• W2552783193 creator A5065894155 @default.
• W2552783193 creator A5079594267 @default.
• W2552783193 date "2015-12-03" @default.
• W2552783193 modified "2023-09-29" @default.
• W2552783193 title "Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors" @default.
• W2552783193 doi "https://doi.org/10.1182/blood.v126.23.62.62" @default.
• W2552783193 hasPublicationYear "2015" @default.
• W2552783193 type Work @default.
• W2552783193 sameAs 2552783193 @default.
• W2552783193 citedByCount "1" @default.
• W2552783193 countsByYear W25527831932016 @default.
• W2552783193 crossrefType "journal-article" @default.
• W2552783193 hasAuthorship W2552783193A5006739024 @default.
• W2552783193 hasAuthorship W2552783193A5032457247 @default.
• W2552783193 hasAuthorship W2552783193A5037029781 @default.
• W2552783193 hasAuthorship W2552783193A5061407928 @default.
• W2552783193 hasAuthorship W2552783193A5065894155 @default.
• W2552783193 hasAuthorship W2552783193A5079594267 @default.
• W2552783193 hasConcept C126322002 @default.
• W2552783193 hasConcept C138496976 @default.
• W2552783193 hasConcept C143998085 @default.
• W2552783193 hasConcept C15744967 @default.
• W2552783193 hasConcept C187212893 @default.
• W2552783193 hasConcept C203014093 @default.
• W2552783193 hasConcept C2776194465 @default.
• W2552783193 hasConcept C2776694085 @default.
• W2552783193 hasConcept C2777408962 @default.
• W2552783193 hasConcept C2778461978 @default.
• W2552783193 hasConcept C2781107101 @default.
• W2552783193 hasConcept C2909962599 @default.
• W2552783193 hasConcept C2911091166 @default.
• W2552783193 hasConcept C3018657049 @default.
• W2552783193 hasConcept C71924100 @default.
• W2552783193 hasConceptScore W2552783193C126322002 @default.
• W2552783193 hasConceptScore W2552783193C138496976 @default.
• W2552783193 hasConceptScore W2552783193C143998085 @default.
• W2552783193 hasConceptScore W2552783193C15744967 @default.
• W2552783193 hasConceptScore W2552783193C187212893 @default.
• W2552783193 hasConceptScore W2552783193C203014093 @default.
• W2552783193 hasConceptScore W2552783193C2776194465 @default.
• W2552783193 hasConceptScore W2552783193C2776694085 @default.
• W2552783193 hasConceptScore W2552783193C2777408962 @default.
• W2552783193 hasConceptScore W2552783193C2778461978 @default.
• W2552783193 hasConceptScore W2552783193C2781107101 @default.
• W2552783193 hasConceptScore W2552783193C2909962599 @default.
• W2552783193 hasConceptScore W2552783193C2911091166 @default.
• W2552783193 hasConceptScore W2552783193C3018657049 @default.
• W2552783193 hasConceptScore W2552783193C71924100 @default.
• W2552783193 hasLocation W25527831931 @default.
• W2552783193 hasOpenAccess W2552783193 @default.
• W2552783193 hasPrimaryLocation W25527831931 @default.
• W2552783193 hasRelatedWork W2001017387 @default.
• W2552783193 hasRelatedWork W2072447072 @default.
• W2552783193 hasRelatedWork W2289642929 @default.
• W2552783193 hasRelatedWork W2504084470 @default.
• W2552783193 hasRelatedWork W2515397117 @default.
• W2552783193 hasRelatedWork W2545515351 @default.
• W2552783193 hasRelatedWork W2548619292 @default.
• W2552783193 hasRelatedWork W2554250903 @default.
• W2552783193 hasRelatedWork W2560566133 @default.
• W2552783193 hasRelatedWork W2573101281 @default.
• W2552783193 hasRelatedWork W2578361185 @default.
• W2552783193 hasRelatedWork W2581839391 @default.
• W2552783193 hasRelatedWork W2591729942 @default.
• W2552783193 hasRelatedWork W2593766771 @default.
• W2552783193 hasRelatedWork W2786688102 @default.
• W2552783193 hasRelatedWork W2983247509 @default.
• W2552783193 hasRelatedWork W2993667630 @default.
• W2552783193 hasRelatedWork W3001043687 @default.
• W2552783193 hasRelatedWork W3013694430 @default.
• W2552783193 hasRelatedWork W3180156062 @default.
• W2552783193 isParatext "false" @default.
• W2552783193 isRetracted "false" @default.
• W2552783193 magId "2552783193" @default.
• W2552783193 workType "article" @default.